Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00399789 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer
A Phase 1 study, sponsored by AEterna Zentaris.
- Completed
- Registry status
- Phase 1
- Development phase
- 121
- Enrollment target
NCT00399789: Completed Phase 1 study, sponsored by AEterna Zentaris.
NCT00399789 is a Phase 1 study that has completed, run by AEterna Zentaris. The registered enrollment target is 121 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (102% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00399789, a Phase 1 study, has completed, sponsored by AEterna Zentaris.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 121 participants
- Enrollment target
Study Summary
This is a study of the drug perifosine that consists of 2 parts. The first part of this study was designed to determine the highest dose of perifosine that can be administered to people every week without severe or prolonged nausea, vomiting and diarrhea. This study started with patients taking 900 mg/week and went up to 1800 mg/week. Part I of this study is completed. The MTD had been determined and incorporated in Part II. The goals in Part II are to: 1. Compare the gastrointestinal toxicity of 3 different dose-schedules and 2. Obtain preliminary information on the response rate of perifosine in non-small cell lung cancer.
Primary Outcome
The frequency of grade 2 or greater gastrointestinal toxicities between the 3 arms of the study will be observed and used to determine the best regimen
Interventions
- DRUG Perifosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 121 participants |
| Start Date | 2004-09 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT00399789 record still lists
NCT00399789 is an interventional study that assigns participants to a tested intervention. The registered 121 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (102% higher).
The record links to 0 conditions, and to 1 intervention - of which Perifosine is the first listed.
NCT00399789 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00399789 about?
NCT00399789 is a clinical study titled "A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer". This is a study of the drug perifosine that consists of 2 parts. The first part of this study was designed to determine the highest dose of perifosine that can be administered to people every week without severe or prolonged nausea, vomiting and diarrhea. This study started with patients taking 900 ...
What is the current status of trial NCT00399789?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 121 participants. The study started on 2004-09. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00399789?
The interventions under investigation include: Perifosine (DRUG).
Who is sponsoring clinical trial NCT00399789?
This trial is sponsored by AEterna Zentaris, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00399789's enrollment target sits among peer trials
121 476th of 2000 higher than 1,522 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03476681 · 121 participants · Phase 1
Study of NEO-201 in Solid Tumors Expansion Cohorts
- NCT04655118 · 121 participants · Phase 2
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
- NCT04676802 · 121 participants · Phase 2
Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
- NCT05169515 · 121 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia